| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2012 | WO2011118818A8 Amidinoaniline derivative |
| 01/26/2012 | WO2011115861A3 Antimicrobial compositions comprising trimethylene glycol oligomer and methods of using the compositions |
| 01/26/2012 | WO2011106702A3 Sustained delivery of therapeutic agents to an eye compartment |
| 01/26/2012 | WO2011106226A3 Prolylhydroxylase inhibitors and methods of use |
| 01/26/2012 | WO2011100295A3 Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase |
| 01/26/2012 | WO2011098194A3 Pharmaceutical mini-tablets for sustained release of flecainide acetate |
| 01/26/2012 | WO2011084548A3 Methods and compositions for detecting recessive familial fsgs and uses thereof |
| 01/26/2012 | WO2011063775A3 Pectin complexes of sartans and pharmaceutical compositions based thereon |
| 01/26/2012 | WO2011023582A3 Use of 1,3-diols as biocides |
| 01/26/2012 | WO2011023540A3 Use of cycloaliphatic diols as biocides |
| 01/26/2012 | WO2010146604A8 Processes for preparing metformin hydrochloride |
| 01/26/2012 | WO2010144140A8 Egfr and par2 regulation of intestinal permeability |
| 01/26/2012 | WO2010143070A3 Amorphous varenicline tartrate co-precipitates |
| 01/26/2012 | WO2010142007A8 Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals |
| 01/26/2012 | US20120022268 New Salt Hydrates |
| 01/26/2012 | US20120022253 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| 01/26/2012 | US20120022167 Trans-Clomiphene for Metabolic Syndrome |
| 01/26/2012 | US20120022166 Methods for Modulating Macrophage Proliferation Using Polyamine Analogs |
| 01/26/2012 | US20120022165 Transdermal compositions |
| 01/26/2012 | US20120022164 External preparation comprising prostaglandin derivative |
| 01/26/2012 | US20120022163 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases |
| 01/26/2012 | US20120022162 Mixed Amino Acid/Mineral Compounds Having Improved Solubility |
| 01/26/2012 | US20120022161 Acetycysteine compositions and methods of use thereof |
| 01/26/2012 | US20120022159 Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof |
| 01/26/2012 | US20120022158 Solid-forming local anesthetic formulations for pain control |
| 01/26/2012 | US20120022157 Dosing and monitoring patients on nitrogen-scavenging drugs |
| 01/26/2012 | US20120022156 Delayed release, oral dosage compositions that contain amorphous cddo-me |
| 01/26/2012 | US20120022155 Use of aminaphtone for the preparation of a medicament for treating arteriopathies |
| 01/26/2012 | US20120022154 N-hydroxy c29-amide derivatives of oleandrane |
| 01/26/2012 | US20120022153 Tricyclic condensed heterocyclic compound, process of producing same, and use thereof |
| 01/26/2012 | US20120022152 Anti-constipation composition |
| 01/26/2012 | US20120022151 Method for preventing damage to nuclear membrane of skin cell by administering amentoflavone |
| 01/26/2012 | US20120022150 Treatment and prevention of benign pigmented moles (naevi) using artemisinine and the derivatives thereof |
| 01/26/2012 | US20120022149 Pharmaceutical composition with enhanced solubility characteristics |
| 01/26/2012 | US20120022148 Curcuminoids in Combination Docetaxel for the Treatment of Cancer and Tumour Metastasis |
| 01/26/2012 | US20120022147 2, 6 xylidine derivatives for the treatment of pain |
| 01/26/2012 | US20120022146 Signal activated molecular delivery |
| 01/26/2012 | US20120022145 Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof |
| 01/26/2012 | US20120022144 Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof |
| 01/26/2012 | US20120022143 RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA) |
| 01/26/2012 | US20120022142 RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 01/26/2012 | US20120022141 Compositions and methods for inhibiting expression of a gene from the jc virus |
| 01/26/2012 | US20120022140 Method of treating a cancer with a survivin antisense oligonucleotide and paclitaxel |
| 01/26/2012 | US20120022139 Short Interfering Ribonucleic Acid (siRNA) for Oral Administration |
| 01/26/2012 | US20120022138 Means for inhibiting the expression of ang2 |
| 01/26/2012 | US20120022137 METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS |
| 01/26/2012 | US20120022136 Cellular Genes Regulated by HIV-1 Infection and Methods of Use Thereof |
| 01/26/2012 | US20120022135 Phd2 inhibition for blood vessel normalization, and uses thereof |
| 01/26/2012 | US20120022134 METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA |
| 01/26/2012 | US20120022133 Antisense modulation of cholesteryl ester transfer protein expression |
| 01/26/2012 | US20120022132 Compositions and methods for inhibiting expression of mutant egfr gene |
| 01/26/2012 | US20120022131 Breast cancer related gene rqcd1 |
| 01/26/2012 | US20120022130 METHOD OF REGULATING NFATc2 ACTIVITY IN LYMPHOCYTES |
| 01/26/2012 | US20120022129 Targeting of Histone Deacetylase 2, Protein Kinase CK2, and Nuclear Factor NRF2 For Treatment of Inflammatory Diseases |
| 01/26/2012 | US20120022128 PKIB and NAALADL2 for Target Genes of Prostate Cancer Therapy and Diagnosis |
| 01/26/2012 | US20120022127 Process for preparing pyrrolidinium salts |
| 01/26/2012 | US20120022126 Method Of Treating Diabetes Mellitus |
| 01/26/2012 | US20120022125 Pyrrolidine triple reuptake inhibitors |
| 01/26/2012 | US20120022124 Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof |
| 01/26/2012 | US20120022123 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof |
| 01/26/2012 | US20120022122 Treatment and prevention of deleterious effects associated with alcohol consumption |
| 01/26/2012 | US20120022121 Indoles, derivatives and analogs thereof and uses therefor |
| 01/26/2012 | US20120022120 Antimycotic pharmaceutical composition |
| 01/26/2012 | US20120022119 Heterocyclic antagonists of prostaglandin d2 receptors |
| 01/26/2012 | US20120022118 Compounds for the treatment of proliferative disorders |
| 01/26/2012 | US20120022117 Salts or Co-Crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| 01/26/2012 | US20120022116 Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| 01/26/2012 | US20120022115 Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases |
| 01/26/2012 | US20120022114 Low-dose, non-irritating nicotine nasal composition to reduce the desire to smoke |
| 01/26/2012 | US20120022113 Methods for suppressing tipdc trafficking or accumulation and preventing hypercytokinemia |
| 01/26/2012 | US20120022111 Spot-on pesticide composition |
| 01/26/2012 | US20120022110 Pharmaceutical depot for 5-fluoro-2-[[(1s)-1-(5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile |
| 01/26/2012 | US20120022109 Oxadiazole derivatives |
| 01/26/2012 | US20120022108 Allosteric modulators of metabotropic glutamate receptors |
| 01/26/2012 | US20120022107 2-(piperidin-1-yl)-4-azolyl-thiazole-5-carboxylic acid derivatives against bacterial infections |
| 01/26/2012 | US20120022106 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 01/26/2012 | US20120022104 Pectin-containing jelly formulation |
| 01/26/2012 | US20120022103 Antagonists of the trpv1 receptor and uses thereof |
| 01/26/2012 | US20120022102 Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof |
| 01/26/2012 | US20120022101 Salt and solvates of a tetrahydroisoquinoline derivative |
| 01/26/2012 | US20120022100 Organic compounds |
| 01/26/2012 | US20120022099 Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative |
| 01/26/2012 | US20120022098 Compounds and methods for kinase modulation, and indications therefor |
| 01/26/2012 | US20120022097 Compositions and Methods for Treating Cancer |
| 01/26/2012 | US20120022096 Pro-neurogenic compounds |
| 01/26/2012 | US20120022095 Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis |
| 01/26/2012 | US20120022094 Pharmaceutical formulations |
| 01/26/2012 | US20120022093 Crystalline forms of oxymorphone hydrochloride |
| 01/26/2012 | US20120022092 Protein kinase c inhibitors and uses thereof |
| 01/26/2012 | US20120022091 Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof |
| 01/26/2012 | US20120022090 Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators |
| 01/26/2012 | US20120022089 Solid Pharmaceutical Dosage Form |
| 01/26/2012 | US20120022088 Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer |
| 01/26/2012 | US20120022087 Amorphous ambrisentan |
| 01/26/2012 | US20120022086 Catecholamine derivatives for obesity and neurological disorders |
| 01/26/2012 | US20120022084 Substituted 5-fluoro-1H-pyrazolopyridines and their use |
| 01/26/2012 | US20120022083 Small molecule modulators of cell adhesion |
| 01/26/2012 | US20120022082 Pyrazine derivatives |
| 01/26/2012 | US20120022081 Method of using diketopiperazines and composition containing them |
| 01/26/2012 | US20120022080 Plasminogen Activator Inhibitor-1 Inhibitor |